Does Mounjaro cause anxiety bad enough to quit in week one?

What's this video probably claiming?

Based on the caption, the creator experienced anxiety during her first week on Mounjaro (tirzepatide) and is using that experience to justify not taking her second injection. The framing is personal testimony, not clinical advice, but with 15.4K views and hashtags like #mounjaroprescription and #mounjarocommunity, the video functions as informal guidance for people starting or considering the drug. The creator signals she's done with the medication after one dose, which implicitly tells her audience that week-one side effects are a valid reason to stop entirely. That conclusion deserves some scrutiny, because anxiety as a standalone reason to discontinue tirzepatide is not well supported by clinical evidence, and the decision to stop a prescribed GLP-1 should involve the prescribing clinician, not a TikTok comment section.

What does the science actually show?

The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) was the important phase 3 study for tirzepatide at 5mg, 10mg, and 15mg doses in adults with obesity. The adverse event data in that trial listed nausea, diarrhea, vomiting, and constipation as the most common side effects, occurring in 12-30% of participants depending on dose. Anxiety was not listed as a statistically significant treatment-emergent adverse event. The FDA prescribing information for Mounjaro does not include anxiety as a common or expected side effect. That said, GLP-1 receptor agonists do affect the central nervous system. Animal studies and some mechanistic research suggest GLP-1 receptors are expressed in brain regions involved in stress response (Kanoski et al., 2016, Physiology and Behavior), but translating rodent neuroscience to human anxiety on week one of a 2.5mg starting dose is a stretch. Nausea-related discomfort and stimulant-like appetite suppression in early weeks could plausibly be interpreted as anxiety by someone not expecting those sensations.

Where does the social media noise diverge from clinical reality?

This is a well-worn pattern in GLP-1 content: week one side effects get labeled as dealbreakers when the clinical protocol is specifically designed to start low and titrate slowly to let the body adjust. The standard starting dose of tirzepatide is 2.5mg weekly for four weeks before any increase. That structure exists precisely because most adverse effects are dose-dependent and time-limited. A 2023 analysis by Wilding et al. in Diabetes Care noted that GI side effects peak in the first four weeks and then decline significantly with continued use. Stopping after one injection means abandoning the drug at its most uncomfortable point before experiencing the therapeutic benefit. Social media creates a selection effect: people who quit in week one make videos; people who pushed through and lost 15-20% of body weight over a year are less likely to frame their story as cautionary. That asymmetry shapes audience perception in ways that don't reflect the actual dropout and outcomes data from trials.

What should you actually know?

If you're on Mounjaro and experiencing feelings you'd describe as anxiety in week one, a few things are worth considering before stopping. First, confirm the symptom with a clinician, because nausea-related unease, heart palpitations from mild dehydration, or stimulant-like appetite suppression can all mimic anxiety and have different clinical meanings. Second, one injection is not enough to judge tolerability. The SURMOUNT trials showed most participants experienced manageable side effects that tapered after the initial titration period. Third, if genuine anxiety or mood changes are occurring, that is worth reporting to your prescriber, not just announcing on TikTok. The FDA adverse event reporting system (FAERS) exists for a reason. Stopping a prescription medication without clinician input, especially one that may be addressing metabolic conditions, is a medical decision that deserves more than a social media caption.